Dementia epidemiology

Medical Clinics of North America

Volumn 86, Issue 3, 2002, Pages 573-590

  Kukull, Walter A ^a   Bowen, James D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; BIOCHEMISTRY; COGNITION; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE IDENTIFICATION; HEREDITY; HUMAN; INCIDENCE; ONSET AGE; PATHOGENESIS; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTECTION; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGIC TEST; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; SURVIVAL; TASK PERFORMANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DEMENTIA; HUMANS; INCIDENCE; PREVALENCE; RISK; UNITED STATES;

EID: 0036323074     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00010-X     Document Type: Review

References (129)

1. Epidemiology of dementia and Alzheimer's disease
2. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
3. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
4. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
5. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers
6. Revised ischemic score for diagnosing multi-infarct dementia
7. The construct validity of the ischemic score of Hachinski for the detection of dementias
8. Hachinski's ischemic score and the diagnosis of vascular dementia: A review
9. Subtypes of vascular dementia
10. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging
11. Vascular dementia: A radical redefinition
12. Multi-infarct dementia: A reappraisal
13. The decline and resurgence of vascular dementia
14. Multi-infarct dementia
15. Operational criteria for senile dementia of Lewy body type (SDLT)
16. Clinical and neuropathological criteria for fronto-temporal dementia
17. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
18. Estimating prevalence and incidence of chronic conditions in the elderly: Design and sampling issues
19. Headache in a population-based elderly cohort. An ancillary study to the Italian Longitudinal Study of Aging (ILSA)
20. The incidence of dementia: A meta-analysis
21. Incidence of dementia and Alzheimer's disease: A reanalysis of data from Rochester, Minnesota, 1975-1984
22. Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia
23. Natural history of vascular dementia
24. Prevention of vascular dementia
25. Vascular dementia: The role of cerebral infarcts
26. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention, and treatment
27. A historical review of the concept of vascular dementia: Lessons from the past for the future
28. Vascular dementia today
29. Clinical criteria for the diagnosis of vascular dementia: A multicenter study of comparability and interrater reliability
30. Vascular risks and incident dementia: Results from a cohort study of the very old
31. Risk factors for vascular disease and dementia
32. Undifferentiated dementia, Alzheimer's disease and vascular dementia: Age- and gender-related incidence in Liverpool. The MRC-ALPHA Study
33. Are vascular factors involved in Alzheimer's disease? Facts and theories
34. Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia
35. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia
36. The prognosis of mild cognitive impairment in the elderly
37. Mild cognitive impairment: Clinical characterization and outcome
38. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
39. Mild cognitive impairment - An early stage of Alzheimer's disease?
40. Early diagnosis of Alzheimer dementia based on clinical and biological factors
41. Early-life risk factors and the development of Alzheimer's disease
42. Smoking and Alzheimer's disease: A review of the epidemiological evidence
43. Smoking and the occurrence of Alzheimer's disease: Cross-sectional and longitudinal data in a population-based study
44. The influence of smoking on the risk of Alzheimer's disease
45. Smoking and dementia in male British doctors: Prospective study
46. The EURODEM collaborative re-analysis of case-control studies of Alzheimer's disease: Implications for public health
47. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype
48. NIH Consensus Statement: Rehabilitation of persons with traumatic brain injury
49. Alzheimer's disease in 22 twin pairs - 13-Year follow-up: Hormonal, infectious and traumatic factors
50. Head trauma and risk of dementia and Alzheimer's disease. The Rotterdam Study
51. Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease
52. Alzheimer's disease after remote head injury: An incidence study
53. Rate of memory decline in AD is related to education and occupation: Cognitive reserve?
54. Cognitive function and apolipoprotein E in very old adults: Findings from the Nun Study
55. Incidence and risk of dementia. The Rotterdam Study
56. Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease
57. Risk factors and differential diagnosis of Alzheimer's disease
58. Low education and childhood rural residence: Risk for Alzheimer's disease in African Americans
59. Education and incident Alzheimer's disease: A biased association due to selective attrition and use of a two-step diagnostic procedure?
60. Cognitive reserve and mortality in dementia: The role of cognition, functional ability and depression
61. Sensitivity and specificity of some neuropsychological markers of Alzheimer dementia
62. Neuropathology of Alzheimer's disease: What is new since A. Alzheimer?
63. Ibuprofen: Effect on inducible nitric oxide synthase
64. Risk of Alzheimer's disease and duration of NSAID use
65. New findings consistent with Alzheimer's-NSAIDs link
66. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
67. NSAIDs and incident Alzheimer's disease. The Rotterdam Study
68. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
69. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal
70. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
71. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study
72. Estrogen use and early onset Alzheimer's disease: A population-based study
73. Alzheimer disease: Protective factors
74. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study
75. Estrogen actions in the central nervous system
76. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
77. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
78. Estrogen, cognition, and a woman's risk of Alzheimer's disease
79. The epidemiology of estrogen replacement therapy and Alzheimer's disease
80. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature
81. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women
82. Post-menopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
83. Hormones and the aging brain
84. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
85. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease
86. Genetic risk factors in Alzheimer's disease
87. The gene defects responsible for familial Alzheimer's disease
88. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders
89. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease
90. Molecular genetics of Alzheimer's disease
91. Alzheimer's disease: Perspectives for the new millennium
92. Genes and susceptible loci of Alzheimer's disease
93. Alzheimer's disease: Genetic studies and transgenic models
94. Recent advances in the genetics of Alzheimer's disease
95. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau
96. Identification of a novel aspartic protease (Asp 2) as beta-secretase
97. The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer's disease
98. Four companies announce discovery of beta-secretase gene
99. Purification and cloning of amyloid precursor protein beta-secretase from human brain
100. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
101. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity
102. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
103. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease
104. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases
105. APOE is a major susceptibility gene for Alzheimer's disease
106. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease
107. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
108. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis
109. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease
110. Genetic association of an alpha2-macroglobulin (Va1100011e) polymorphism and Alzheimer's disease
111. Lack of association of the alpha2-macroglobulin locus on chromosome 12 in AD
112. Alpha2 macroglobulin and the risk of Alzheimer's disease
113. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
114. Association between an alpha(2) macroglobulin DNA polymorphism and late-onset Alzheimer's disease
115. No association between the HLA-A2 allele and Alzheimer disease
116. Mutation screening of the tau gene in patients with early-onset Alzheimer's disease
117. Homocysteine and risk of stroke
118. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12
119. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
120. Mitochondrial genome lesions in the pathogenesis of sporadic Alzheimer's disease
121. Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's disease
122. Mitochondrial DNA mutations in Alzheimer's disease
123. Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes
124. Mutations in the tau gene cause frontotemporal dementia
125. A polymorphism in the tau gene associated with risk for Alzheimer's disease